MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Dec 10, 2019

Sanofi (SNY, $47.69) will acquire Synthorx for $2.5 billion

France’s pharmaceutical company Sanofi will buy biotech company Synthorx.

Sanofi will pay  $68 cash a share, or $2.5 billion for the acquisition. Synthorx  is focused on treating cancer and autoimmune disorders.

The deal, expected to close in the first quarter next year, is expected to boost Sanofi’s immuno-oncology portfolio, as indicated by the company.

In a separate announcement,  Sanofi revealed  that its Sanofi Pasteur global vaccines unit entered a $226 million collaboration with the U.S. Department of Health and Human Services, to increase the company’s domestic pandemic influenza vaccine production capabilities at its Swiftwater, Pa., plant.

Related Ticker: SNY

SNY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SNY turned positive on July 01, 2025. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on SNY as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where SNY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

SNY moved below its 50-day moving average on June 13, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SNY crossed bearishly below the 50-day moving average on June 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for SNY moved below the 200-day moving average on June 03, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNY entered a downward trend on June 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.508) is normal, around the industry mean (5.632). P/E Ratio (20.803) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.869) is also within normal values, averaging (3.004). Dividend Yield (0.039) settles around the average of (0.161) among similar stocks. P/S Ratio (2.420) is also within normal values, averaging (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 9%. SCLX experienced the highest price growth at 5%, while DSKYF experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was 27% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 72
Price Growth Rating: 54
SMR Rating: 58
Profit Risk Rating: 79
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
46, avenue de la Grande Armée
Phone
+33 153774000
Employees
87994
Web
https://www.sanofi.com